Howard L. Kaufman
YOU?
Author Swipe
View article: 631 Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors
631 Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors Open
View article: 1195 Evaluation of alum-anchored IL-12 (JEN-101) immunotherapy in canine melanoma: safety and efficacy across weight-based and tumor volume dosing strategies
1195 Evaluation of alum-anchored IL-12 (JEN-101) immunotherapy in canine melanoma: safety and efficacy across weight-based and tumor volume dosing strategies Open
View article: 189 Baseline NKT cells as a potential predictive biomarker for treatment with an anchored IL-12 drug conjugate in patients with solid tumors
189 Baseline NKT cells as a potential predictive biomarker for treatment with an anchored IL-12 drug conjugate in patients with solid tumors Open
View article: Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors
Molecular Plasticity of T Cells Informs Their Possible Adaptation in 4T1 Tumors Open
Background The triple-negative breast cancer (TNBC) microenvironment (TME) undergoes progressive reprogramming, transitioning from an early immune-active state to a late immune-suppressed state. While tumor cell plasticity has been extensi…
View article: Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors
Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors Open
View article: Figures raw data & plotting code from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Figures raw data & plotting code from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
The file contains the raw data for figures 2,3A, 3B,4,5 & 6 with corresponding plotting code.
View article: Supplementary Table S2 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Supplementary Table S2 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
Supplementary Table S2 shows the final parameter values of mouse PK model.
View article: Supplementary Table S3 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Supplementary Table S3 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
Supplementary Table S3 shows the Model fit comparisons of different biomarkers with the base tumor growth model in CT26 tumors.
View article: Supplementary Table S4 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Supplementary Table S4 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
Supplementary Table S4 shows the final parameter values describing the full PK/PD model.
View article: Supplementary Table S1 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Supplementary Table S1 from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
Supplementary Table S1 shows the list of antibodies used during flow cytometry for immunophenotypic analysis.
View article: Data from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
Data from A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
IL-12 mediates innate and adaptive immune responses and has demonstrated therapeutic antitumor activity, but clinical development has been hindered by a narrow therapeutic window. We generated a novel IL-12–anchored drug conjugate by physi…
View article: Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference
Updates on radiotherapy-immunotherapy combinations: Proceedings of 8th Annual ImmunoRad Conference Open
The annual ImmunoRad Conference has established itself as a recurrent occasion to explore the possibility of combining radiation therapy (RT) and immunotherapy (IT) for clinical cancer management. Bringing together a number of preclinical …
View article: Percutaneous Microwave Ablation of Small (<4 cm) Renal Masses Performed under Moderate Sedation
Percutaneous Microwave Ablation of Small (<4 cm) Renal Masses Performed under Moderate Sedation Open
MWA of small renal masses under moderate sedation alone demonstrates excellent patient safety profile, tolerability, and effectiveness, allowing operational efficiency, including short procedure times and same-day discharge.
View article: A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors
A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors Open
IL-12 mediates innate and adaptive immune responses and has demonstrated therapeutic antitumor activity, but clinical development has been hindered by a narrow therapeutic window. We generated a novel IL-12–anchored drug conjugate by physi…
View article: Supplementary Figure S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Safety hematological and biochemical profile of JEN-101 treatment.
View article: Supplementary Figure S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Patient 006 treated with JEN-101 and a CTLA-4 inhibitor.
View article: Supplementary Table S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Table S1 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
JEN-101 dosing and volumes for injection in clinical trial.
View article: Supplementary Figure S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Circulating c-IL-12-ABP levels in patient 010.
View article: Supplementary Table S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Table S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Summary of anti-drug antibody titers at indicated timepoint by ELISA.
View article: Supplementary Table S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Table S3 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Best response observed in treated evaluable patients by investigator assessment.
View article: Supplementary Table S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Table S4 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Pharmacokinetic parameters of JEN-101.
View article: Supplementary Figure S8 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S8 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Dose/Tumor Volume ratio and correlation with best response.
View article: Supplementary Figure S6 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S6 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Circulating IL-10 response to treatment with JEN-101.
View article: Supplementary Figure S9 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S9 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Immunohistochemical analysis of the excised lesion from patients 008 and 014 reveals morphological changes indicative of granulomatous inflammation.
View article: Supplementary Table S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Table S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Incidence of JEN-101 adverse events in 2 or more dogs.
View article: Supplementary Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Supplemental Data File containing raw data generated in this study.
View article: Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Data from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Melanoma is an aggressive cancer in dogs involving skin and mucosa similar to humans. Anchored immunotherapeutics offer a novel approach to increase intratumoral retention of therapeutic payloads while decreasing systemic exposure, and thi…
View article: Supplementary Figure S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S2 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
NanoString RNA cell type profiling and pathway scores of primary tumor lesions.
View article: Supplementary Figure S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S5 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
Characterization of anti-drug antibody (ADA) responses in dogs at day 63 (dose 4).
View article: Supplementary Figure S7 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma
Supplementary Figure S7 from Preclinical Evaluation of an Anchored Immunotherapy Strategy with Aluminum Hydroxide–Tethered IL-12 in Dogs with Advanced Malignant Melanoma Open
CD3+ T lymphocytes and IBA1+ macrophage infiltration prior and after administration of JEN-101.